Research programme: long-acting neurokines - Temper Bio
Alternative Names: TAFA-4 fusion proteins - Temper BioLatest Information Update: 04 Nov 2025
At a glance
- Originator Temper Bio
- Class Anti-inflammatories; Cytokines; Recombinant fusion proteins
- Mechanism of Action TAFA4 protein replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Inflammation
- Research Multiple sclerosis
Most Recent Events
- 31 Oct 2024 Preclinical trials in Inflammation in France (Parenteral), before October 2025 (Argobio Studio website, October 2025)